Subclinical Thyroid Dysfunction: When to treat and when to observe. A comprehensive clinical review

Abstract

Subclinical thyroid dysfunction (STD) - encompassing subclinical hypothyroidism (SCH) and subclinical hyperthyroidism (SHT) - represents one of the most prevalent and clinically nuanced endocrine conditions encountered in general practice. Defined by abnormal serum thyroid-stimulating hormone (TSH) levels in the presence of normal free thyroxine (FT4) and free triiodothyronine (FT3), these conditions affect an estimated 5–10% of the general adult population, with disproportionately higher prevalence among women and individuals over the age of 65.

The fundamental clinical dilemma lies in determining when pharmacological intervention is warranted versus when a strategy of watchful waiting is more appropriate. Premature or indiscriminate treatment carries its own risks - iatrogenic hyperthyroidism, bone loss, and cardiovascular strain - while untreated dysfunction may progress to overt disease or silently contribute to metabolic, cardiac, or cognitive morbidity.

This review synthesizes current evidence and reconciles the recommendations of major international bodies - the American Thyroid Association (ATA), the European Thyroid Association (ETA), and the Polish Society of Endocrinology (PTE) - to present a practical, patient-centered decision framework. Special emphasis is placed on age-adapted TSH reference ranges, the distinct risks posed by each form of STD, and the clinical circumstances that should guide individualized management. The overarching conclusion is that rigid, threshold-based decision-making is insufficient; instead, treatment decisions must integrate TSH magnitude, clinical symptoms, comorbidities, patient age, reproductive status, and serological markers such as anti-thyroid peroxidase (anti-TPO) antibodies.